Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ILMN Stock Forecast 2026-2027
$160.97
Current Price
$24.35B
Market Cap
Buy 10
Hold 5
Sell 4
Wall St Analyst Ratings
Distance to ILMN Price Targets
+11.8%
To High Target of $180.00
-8.4%
To Median Target of $147.50
-41.0%
To Low Target of $95.00
ILMN Price Momentum
+1.9%
1 Week Change
+12.9%
1 Month Change
+85.2%
1 Year Change
+22.7%
Year-to-Date Change
-9.2%
From 52W High of $177.22
+87.7%
From 52W Low of $85.77
📊 TOP ANALYST CALLS
Did ILMN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Illumina is one of their latest high-conviction picks.
Latest ILMN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ILMN has a bullish consensus with a median price target of $147.50 (ranging from $95.00 to $180.00). The overall analyst rating is Buy (7.3/10). Currently trading at $160.97, the median forecast implies a -8.4% downside. This outlook is supported by 10 Buy, 5 Hold, and 4 Sell ratings.
The most optimistic forecast comes from Subbu Nambi at Guggenheim, projecting a 11.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ILMN Analyst Ratings
10
Buy
5
Hold
4
Sell
ILMN Price Target Range
Low
$95.00
Average
$147.50
High
$180.00
Current: $160.97
Latest ILMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ILMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2026 | JP Morgan | Casey Woodring | Overweight | Upgrade | $185.00 |
| Jun 1, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $180.00 |
| May 15, 2026 | RBC Capital | Dan Leonard | Outperform | Reinstates | $170.00 |
| May 4, 2026 | Citigroup | Sell | Maintains | $N/A | |
| May 1, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| May 1, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| May 1, 2026 | Barclays | Underweight | Maintains | $N/A | |
| May 1, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 9, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 6, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| Jan 26, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jan 26, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Jan 20, 2026 | Stifel | Buy | Maintains | $N/A | |
| Jan 7, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Jan 5, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 22, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Dec 15, 2025 | Barclays | Underweight | Maintains | $N/A | |
| Dec 15, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Oct 31, 2025 | Barclays | Underweight | Maintains | $N/A | |
| Oct 31, 2025 | Canaccord Genuity | Hold | Maintains | $N/A |
Illumina, Inc. (ILMN) Competitors
The following stocks are similar to Illumina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Illumina, Inc. (ILMN) Financial Data
Illumina, Inc. has a market capitalization of $24.35B with a P/E ratio of 30.2x. The company generates $4.39B in trailing twelve-month revenue with a 19.4% profit margin.
Revenue growth is +4.8% quarter-over-quarter, while maintaining an operating margin of +18.3% and return on equity of +33.8%.
Valuation Metrics
Market Cap
$24.35B
Enterprise Value
$25.97B
P/E Ratio
30.2x
PEG Ratio
5.0x
Price/Sales
5.7x
Growth & Margins
Revenue Growth (YoY)
+4.8%
Gross Margin
+66.1%
Operating Margin
+18.3%
Net Margin
+19.4%
EPS Growth
+2.3%
Financial Health
Cash/Price Ratio
+4.7%
Current Ratio
1.7x
Debt/Equity
95.1x
ROE
+33.8%
ROA
+8.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Illumina, Inc. (ILMN) Business Model
About Illumina, Inc.
What They Do
Develops tools for genetic material analysis.
Business Model
Illumina generates revenue by selling next-generation sequencing instruments, consumables, and related services to research, clinical, and applied markets. The company also provides microarray products and offers sequencing services, instrument monitoring, and consulting, making it a comprehensive provider in the genomics field.
Additional Information
Founded in 1998 and headquartered in San Diego, California, Illumina is pivotal in advancing genomic research and clinical diagnostics. Its diverse applications span oncology, rare diseases, reproductive health, and agriculture, positioning the company as a leader in the life sciences and diagnostics industry.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
8,600
CEO
Mr. Jacob Thaysen Ph.D.
Country
United States
IPO Year
2000
Website
www.illumina.comIllumina, Inc. (ILMN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jun 11, 2026
By Zacks Equity Research
Tale of the Tape
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Zacks Premium offers Style Scores to help all types of investors—value, growth, or momentum—identify strong stocks more easily.
Why It Matters
Zacks Style Scores aid in identifying strong stocks across investment strategies, enhancing decision-making for investors seeking better returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Illumina has broken out of an inverse head and shoulders pattern, maintaining a bullish outlook with key support levels holding and upside targets in focus.
Why It Matters
Illumina's breakout from a bullish pattern signals potential price appreciation, attracting investor interest and suggesting future growth opportunities. Key support enhances confidence in stability.
Source: FXEmpire
Market Sentiment:
Positive
Quick Summary
Illumina launched the StrataMap Spatial Solution, enhancing spatial transcriptomics with whole-transcriptome profiling, potentially doubling unique gene detection compared to probe-based methods.
Why It Matters
Illumina's launch of StrataMap Spatial enhances genomic research capabilities, potentially driving demand for its technology and boosting market position, impacting future revenue and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Illumina shares rose 98.7% over the past year, driven by increased adoption of NovaSeq X, growing clinical sequencing demand, and exceeding Q1 2026 guidance.
Why It Matters
Illumina's significant share surge indicates strong market confidence, driven by increased demand for sequencing and positive earnings guidance, suggesting robust future growth potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Genomics and synthetic biology are transforming healthcare, increasing demand for precision medicine and positively impacting stocks such as PACB, MYGN, and TWST.
Why It Matters
Rising demand for precision medicine boosts interest in genomics stocks like PACB, MYGN, and TWST, indicating potential growth and investment opportunities in the healthcare sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IDT's library prep solutions are now integrated with Illumina's software ecosystem, enhancing analysis for FFPE and cfDNA workflows.
Why It Matters
IDT's integration with Illumina enhances workflow efficiency in genetic analysis, potentially boosting demand for both companies' products and impacting their market valuations positively.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ILMN Stock
What is Illumina, Inc.'s (ILMN) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Illumina, Inc. (ILMN) has a median price target of $147.50. The highest price target is $180.00 and the lowest is $95.00.
Is ILMN stock a good investment in 2026?
According to current analyst ratings, ILMN has 10 Buy ratings, 5 Hold ratings, and 4 Sell ratings. The stock is currently trading at $160.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ILMN stock?
Wall Street analysts predict ILMN stock could reach $147.50 in the next 12 months. This represents a -8.4% decrease from the current price of $160.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Illumina, Inc.'s business model?
Illumina generates revenue by selling next-generation sequencing instruments, consumables, and related services to research, clinical, and applied markets. The company also provides microarray products and offers sequencing services, instrument monitoring, and consulting, making it a comprehensive provider in the genomics field.
What is the highest forecasted price for ILMN Illumina, Inc.?
The highest price target for ILMN is $180.00 from Subbu Nambi at Guggenheim, which represents a 11.8% increase from the current price of $160.97.
What is the lowest forecasted price for ILMN Illumina, Inc.?
The lowest price target for ILMN is $95.00 from at , which represents a -41.0% decrease from the current price of $160.97.
What is the overall ILMN consensus from analysts for Illumina, Inc.?
The overall analyst consensus for ILMN is bullish. Out of 6 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 4 as Sell, with a median price target of $147.50.
How accurate are ILMN stock price projections?
Stock price projections, including those for Illumina, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:07 AM UTC